Lin Mei
@LinMeiMD_onc
Genitourinary Oncology, Penn Medicine, Abramson Cancer Center. Interested in rare GU malignacies, cancer immunology and brain metastasis. Tweets are my own view
Appreciated all the staffs. It is a lot of effort.
The Oncology Evaluation Center helps cancer patients with complications that arise in between scheduled treatments—easing their care and their anxiety. Open 24/7, it’s a place where patients can go for help with side effects, bypassing the emergency room. spr.ly/60157OiBU
Radiation oncologists are trained to deliver safe, high-precision radiotherapy as part of a #cancer care team. We follow the best available evidence & develop customized, cost-effective plans. Science guides our treatments, but humanity guides our practice. 1/2
In the News: ASTRO marks President Biden’s treatment milestone with ASTRO President Neha Vapiwala, MD leading the treatment team. @NehaVapiwala @SameerKeoleMD @PennMedicine @JoeBiden ow.ly/yCUo50XgSQh
Wow. Penn Medicine is the best. Appreciate @NehaVapiwala
Congratulations to President @JoeBiden for finishing RT under the care of @ASTRO_org President @NehaVapiwala @PennMedicine #radonc
Excited to share our recent @LancetOncology publication on sequential SBRT for oligometastatic clear cell RCC. Our outcomes show excellent outcomes in 121 patients with 1-5 metastases. @MDAndersonNews @myriadgenetics authors.elsevier.com/a/1ljMf5EIIgTS…
I will change again.
The +ve periopertive EVP trial for OS in cis ineligible MIBC may open a new area. Especially if its like EVP in M1 disease. 3 more trials in this area are awaited which test 1) EVP vs cisplatin (NIAGARA population), 2) EV/PD1/CTLA4 vs surgery 3) treatment based on ctDNA status.
A mind-opener review on muscle-invasive bladder cancer. Must-read for GU oncologist. #BladderCancer #Oncology #Immunotherapy @MattGalsky @l_ballas @UroDocAsh @ASCO @JCO_ASCO @WorldBladderCan @OncoAlert @OncBrothers @Uromigos @urologysummit doi.org/10.1200/JCO-25…
Our study regarding the race, sex and age disparity in metastatic bladder cancer. Actually, female sex and older patients didn't show worse outcomes than the comparators. clinical-genitourinary-cancer.com/article/S1558-…
Congratulations and thanks for the effort from everybody!
There are still disparities in #bladdercancer survival across the US: we found women had faster progression on #immunotherapy, while Asian patients lived longer than Black or White patients. Thank you @LinMeiMD_onc @Ron_cology @Omelghawy @flatironhealth clinical-genitourinary-cancer.com/article/S1558-…
Terrific presentation by #VivekNarayan Ab#4507 @ASCO #ASCO25 👉5-yr f/u of Ph2 LITESPARK-004👉Belzutifan shows durable activity and manageable toxicity in VHL-associated neoplasms (ORR 70% in RCC) #kidneycancer👇@OncoAlert @urotoday @kidneycancer
Congratulations Vivek! @Ron_cology @PennCancer
Vivek Narayan, MD, MS receives the 2025 Pearl and Phil Innovation Research Award for his work impacting male BRCA mutation carriers as a prostate cancer clinical investigator improving treatments for BRCA-related prostate cancer and overcoming treatment resistance. @PennCancer
One of my patient was in this trial. Amazing work from Penn. @PennCancer Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure | New England Journal of Medicine nejm.org/doi/full/10.10…
A @PennMedicine pilot study led by Ronac Mamtani, MD (@Ron_cology), demonstrated that text message check-ins, instead of in-person visits, could save cancer patients more than 60 minutes per appointment. @HemOncToday spr.ly/60122Rwj0
Specially interested to see 1 and 2.
Bladder cancer highlights #ASCOGU25 1) outcomes of pCR patients for gem/cis/durvalumab (NIAGARA) 2) neoadjuvant gem/cis/durvalumab in upper tract disease 3) Neoadjuvant DV/PD1 in MIBC (pCR >50%?) 3) Longer OS follow up for EVP 4) Data on DDXD and new FGFR3i in pretreated patients
Just in @CACancerJournal 👉Comprehensive review of efficacy & safety data of PARP inhibitors across cancer types #prostatecancer, #ovariancancer, #breastcancer & others 👉Open access weblink👉 bit.ly/42apBgy @chadihc98 @Huntsman_GU @OncoAlert @urotoday @PCF_Science
From @asco @JCOOP_ASCO 71% of US counties either lack an oncologist (20%) or lack an open cancer trials (50%). Meanwhile trends show declining % of oncologists in rural communities. Pair this with @wsj piece on community oncs being overwhelmed by clinical advances.
Legendary
Mil gracias a todos Many thanks to all Merci beaucoup à tous Grazie mille à tutti 谢谢大家 شكرا لكم جميعا תודה לכולכם Obrigado a todos Vielen Dank euch allen Tack alla Хвала свима Gràcies a tots
Thanks for our resident @ABarsouk hard work and dedication. Appreciate @Ron_cology support for your review article. We have found women's bladder cancer still has inferior outcomes even in the modern treatment era.
Meta-Analysis of Age, Sex, and Race Disparities in the Era of Contemporary Urothelial Carcinoma Treatment mdpi.com/2977898 #mdpicancers via @Cancers_MDPI
Meta-Analysis of Age, Sex, and Race Disparities in the Era of Contemporary Urothelial Carcinoma Treatment mdpi.com/2977898 #mdpicancers via @Cancers_MDPI
Nice summary.
A summary of the ADC session at #UromigosLive24 with @apolo_andrea @shilpaonc @PGrivasMDPhD @tompowles1 & @kalasri3
Excellent review
From @JAMA_current: Renal cell carcinoma (RCC) is a common cancer, with an estimated 434 840 incident cases worldwide in 2022. This review summarizes the epidemiology, clinical presentation, pathophysiology, and management of RCC. ja.ma/4ezLtVm
United States Trends
- 1. #lip_bomb_RESCENE N/A
- 2. Ravens 58.4K posts
- 3. Ravens 58.4K posts
- 4. Lamar 46.4K posts
- 5. #heatedrivalry 14.7K posts
- 6. ilya 16.7K posts
- 7. shane 20.1K posts
- 8. #River 3,134 posts
- 9. Joe Burrow 21K posts
- 10. Hudson 11.9K posts
- 11. Connor 15.1K posts
- 12. Zay Flowers 4,187 posts
- 13. #WhoDey 4,139 posts
- 14. Chiefs 109K posts
- 15. #hrspoilers 2,847 posts
- 16. Sarah Beckstrom 221K posts
- 17. scott hunter N/A
- 18. Derrick Henry 4,470 posts
- 19. Third World Countries 26.7K posts
- 20. Mahomes 34.3K posts
Something went wrong.
Something went wrong.